Sun Pharma to focus on R&D after Ranbaxy buyout
Sun Pharma said that the combined entity will expand R&D capabilities and global presence that can lead to a value accretion of $250 million over three years.
Mail Today Bureau
New Delhi Last Updated: March 26, 2015 | 08:24 IST
File picture of Sun Pharma founder and managing director Dilip Shanghvi (Source: Reuters)